Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in non-first-line treatment of metastatic cancer
ChiCTR-OIC-17013238Phase 2Recruiting
- Sponsor
- The Sixth Affiliated Hospital, South China University of Technology
- Start
- Aug 2015
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in metastasis, sponsored by The Sixth Affiliated Hospital, South China University of Technology. Primary endpoint: Progression-free survival. Started Aug 2015; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
metastasis
Beyond the preview
Go deeper on ChiCTR-OIC-17013238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17013238.